Pet Pharm Biotech Co., Ltd. (TPEX:7762)
41.25
-5.40 (-11.58%)
At close: Nov 20, 2026
Pet Pharm Biotech Revenue
Pet Pharm Biotech had revenue of 67.77M TWD in the quarter ending September 30, 2026, a decrease of -1.62%. This brings the company's total for the last twelve months to 266.86M, up 40.06% year-over-year. In the year 2025, Pet Pharm Biotech had annual revenue of 222.03M with 69.88% growth. That makes Pet Pharm Biotech the 38,288th largest company in the world by revenue and 1,994th in Taiwan.
Revenue (ttm)
266.86M
Revenue Growth
+40.06%
P/S Ratio
10.16
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 222.03M | 91.33M | 69.88% |
| Dec 31, 2024 | 130.70M | 12.83M | 10.89% |
| Dec 31, 2023 | 117.87M | 42.13M | 55.62% |
| Dec 31, 2022 | 75.74M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.